SecBot SecBot
SECBOTREPLAY Home › Report › KROS

KROS · Keros Therapeutics is holding its 2026 annual shareholder meeting…

Keros Therapeutics, Inc. · DEFA14A filed Apr 22, 2026 at 16:03 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 22, 2026 at 16:03 ET

Keros Therapeutics is holding its 2026 annual shareholder meeting virtually on June 3, 2026. The board recommends voting for the election of Jean-Jacques Bienaimé and Charles Newton as Class III directors, ratifying Deloitte & Touche LLP as auditors, and approving executive compensation.

  • Annual meeting date: June 3, 2026
  • Meeting will be held virtually
  • Board recommends voting FOR all proposals
  • Proposal 1: Elect Jean-Jacques Bienaimé and Charles Newton as Class III directors

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access